INSUBCONTINENT EXCLUSIVE:
Blame it on lifestyle changes or poor dietary practices, lack of Vitamin D poses a problem for many in urban areas
But when juxtaposed with Dalal Street, they are a market opportunity for others.
As many as 8 out of 10 people in Delhi suffer from Vitamin
D deficiency, according to a report by Assocham (Associated Chambers of Commerce and Industry of India).
Going by some media reports, the
global market for Vitamin D may hit $2.5 billion by 2020 growing at a CAGR of 11 per cent
That's music to the ears of those which manufacture such drugs.
Notable players are Alkem Laboratories, Abbott India and Sanofi India with
a sizeable share in Vitamin D3 market
Vitamin D3 is the recommended form of vitamin D
This is also the natural form of the vitamin that body gets from sunlight
Changing lifestyles where one spends more time indoors, poor dietary habits and rising pollution level have all contributed to the
The company has a robust manufacturing infrastructure consisting of 21 manufacturing facilities across India and the US
It's a pan-India player with an extensive sales, marketing and distribution network with over 8,000 medical representatives, nearly 7,000
stockists and more than 40 sales depots and warehouses.
The company was listed on the NSE and the BSE in December 2015 and has a market
capitalisation of Rs 24,832 crore as on September 17, 2018
Alkem Laboratories with a target price of Rs 2,390.
Arachitol Nano (Vitamin D preparations) from Abbott India holds 6.06 per cent market
share in the D3 category, says a news report
vitamins, vaccines and the like
Abbott posted strong growth in Q1 2018-19 with topline displaying decent YoY growth of 20 per cent at Rs 845 crore while bottom line
Its robust plan to launch 100 new products over five years coupled with strong sectoral outlook make the stock an attractive destination to
deploy the funds at the current level
product, Depura of Sanofi India takes more than 5 per cent market share in the vitamin D3 segment, a report showed
The products manufactured by the company are distributed in India and exported to 51 countries (in CY17), with Germany, Australia, the UK,
Russia, Czech Republic and Italy making up as the main markets
Four products of company, including Lantus, Combiflam, Amaryl and Allegra, feature in the top 100 pharmaceutical brands of India.
For the
June quarter, the company posted a 15 per cent year-on-year growth in revenue figures while profit jumped 35 per cent on a yearly basis
class population coupled with improving medical infrastructure and rising insurance penetration, better diagnosis of chronic,
non-communicable diseases (like cardiovascular diseases, respiratory diseases and type-2 Diabetes) and new product launches like Combiflam
Cadila Pharma and D3 Must by Mankind Pharma command 11.49 per cent and 4.93 per cent market share, respectively
However, these companies are not listed on the BSE and the NSE as well
Index-wise, the Nifty Pharma outperformed the benchmark NSE Nifty by 10 percentage points during the past three months
The pharma index rallied nearly 17 per cent to 10,652.90 on September 14, from 9,112.50 on June 14, while the Nifty jumped 6.54 per cent to
11,515.20 from 10,808.10 during the same period.
Global brokerage firm CLSA said the recent rally is a result of the recent forex tailwinds,
improving pricing commentary in the US, normalcy in the domestic market, minimal earnings cut in Q1 and certain complex or specialty
potential earnings upgrade in the near term In the medium term, sustained improvement in US dynamics will be critical to support the
The brokerage firm favours Sun Pharma and Cipla in the pharmaceutical space.
